DIVI'S LABORATORIES
- Advice
- Hold
Divi's Laboratories Share Price
Divi's Laboratories Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Divi's Laboratories Investment Rating
-
Master Rating:
-
Divis Laboratories (Nse) has an operating revenue of Rs. 9,253.71 Cr. on a trailing 12-month basis. An annual revenue growth of 29% is outstanding, Pre-tax margin of 41% is great, ROE of 25% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 98 which is a GREAT score indicating consistency in earnings, a RS Rating of 15 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
- Indicator
- Jun 2022
- Mar 2022
- Dec 2021
- Sep 2021
- Jun 2021
- Mar 2021
- Oper Rev Qtr Cr
- 2,204
- 2,495
- 2,467
- 1,968
- 1,950
- 1,718
- Operating Expenses Qtr Cr
- 1,366
- 1,399
- 1,367
- 1,149
- 1,099
- 1,019
- Operating Profit Qtr Cr
- 838
- 1,096
- 1,100
- 819
- 851
- 699
- Depreciation Qtr Cr
- 83
- 81
- 80
- 77
- 73
- 70
- Interest Qtr Cr
- 0
- 0
- 0
- 0
- 0
- 0
- Tax Qtr Cr
- 152
- 183
- 129
- 154
- 262
- 164
- Net Profit Qtr Cr
- 692
- 883
- 907
- 606
- 552
- 488
Divi's Laboratories Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 1
- Bearish Moving Average
- ___
- 15
- 20 Day
- 3818.15
- 50 Day
- 3804.82
- 100 Day
- 3938.7
- 200 Day
- 4251.99
- 20 Day
- 3814.17
- 50 Day
- 3685.9
- 100 Day
- 3976.58
- 200 Day
- 4250.93
Divi's Laboratories Resistance and Support
- First Resistance
- 3967.05
- Second Resistance
- 3986.05
- Third Resistance
- 4017.05
- First Resistance
- 3917.05
- Second Resistance
- 3886.05
- Third Resistance
- 3867.05
- RSI
- 43.91
- MFI
- 47.27
- MACD Single Line
- 45.66
- MACD
- 45.13
Divi's Laboratories Delivery and Volume
- Period
- NSE + BSE
Volume Avg - NSE + BSE
Delivery Volume Avg - NSE + BSE
Delivery Volume %
- Day
- 2,239,149
- 81,885,679
- 36.57
- Week
- 784,110
- 32,242,613
- 41.12
- 1 Month
- 422,149
- 18,591,459
- 44.04
- 6 Month
- 537,480
- 24,369,321
- 45.34
Divi's Laboratories Result Highlights
Divi's Laboratories Synopsis
NSE-Medical-Generic Drugs
Divi's Lab is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 8879.82 Cr. and Equity Capital is Rs. 53.09 Cr. for the Year ended 31/03/2022. Divi's Laboratories Ltd. is a Public Limited Listed company incorporated on 12/10/1990 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1990PLC011854 and registration number is 011854.- Market Cap
- 98,919
- Sales
- 9,134
- Shares in Float
- 12.74
- No of funds
- 791
- Yield
- 0.81
- Book Value
- 8.46
- U/D Vol ratio
- 1.1
- LTDebt / Equity
- Alpha
- -0.12
- Beta
- 0.84
Divi's Laboratories
- Owner Name
- Jun-22
- Mar-22
- Dec-21
- Sep-21
- Promoters
- 51.94%
- 51.94%
- 51.95%
- Mutual Funds
- 13.85%
- 13.68%
- 13.35%
- Foreign Portfolio Investors
- 16.52%
- 18.45%
- 19.3%
- Financial Institutions/ Banks
- 0.09%
- 0.05%
- 0.05%
- Individual Investors
- 9.53%
- 9.27%
- 9.01%
- Others
- 8.07%
- 6.61%
- 6.34%
Divi's Laboratories Management
- Name
- Designation
- Dr. Ramesh B V Nimmagadda
- Non Exe.Chairman&Ind.Director
- Dr. Murali K Divi
- Managing Director
- Dr. Kiran S Divi
- WholeTime Director & CEO
- Ms. Nilima Prasad Divi
- Whole Time Director
- Mr. Madhusudana Rao Divi
- Whole Time Director
- Mr. N V Ramana
- Executive Director
- Mr. K V K Seshavataram
- Independent Director
- Dr. G Suresh Kumar
- Independent Director
- Mr. R Ranga Rao
- Independent Director
- Prof. Sunaina Singh
- Independent Director
- Dr. S Ganapaty
- Independent Director
- Mr. K V Chowdary
- Independent Director
Divi's Laboratories Forecast
Price Estimates
Divi's Laboratories Corporate Action
Divi's Laboratories FAQs
What is Share Price of Divi's Laboratories ?
Divi's Laboratories share price is ₹3726 As on 14 August, 2022 | 12:31
What is the Market Cap of Divi's Laboratories ?
The Market Cap of Divi's Laboratories is ₹98918.9 Cr As on 14 August, 2022 | 12:31
What is the P/E ratio of Divi's Laboratories ?
The P/E ratio of Divi's Laboratories is 31.9 As on 14 August, 2022 | 12:31
What is the PB ratio of Divi's Laboratories ?
The PB ratio of Divi's Laboratories is 8.4 As on 14 August, 2022 | 12:31
What does Divis Laboratories do?
Divis Laboratories Ltd is an active pharmaceutical ingredient (API) and intermediates company situated in India. Divis Laboratories specialises in the production of leading generic chemicals, nutraceutical components, and custom API and intermediate synthesis for worldwide innovators.
Is Divis Laboratories good for the long term?
Divis Laboratories has an operating revenue of INR 7,437.78 Cr. on a trailing 12-month basis. Annual revenue growth of 26% is outstanding, Pre-tax margin of 38% is great, ROE of 21% is exceptional. Institutional holding in Divis Laboratories has gone up in the last reported quarter is a positive sign. As per analysts rating in the last 6 months, the recommendation is to HOLD Divis Laboratories.
Is Divis Laboratories debt-free?
Divis Laboratories is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.
Who is the owner of Divis Laboratories?
Murali Divi is the founder of Divis Laboratories, one of the top three manufacturers of active pharmaceutical ingredients (API).